Table 1.
Sustained virologic response according to patient characteristics at baseline (n = 288) n (%)
|
Achieved SVR |
P value | ||
| Yes (n = 237) | No (n = 51) | ||
| Demographics | |||
| Sex | |||
| Male | 101 (87.1) | 15 (12.9) | 0.081 |
| Female | 136 (79.1) | 36 (20.9) | |
| Age | |||
| Mean ± SD | 45.9 ± 10.4 | 50.1 ± 8.5 | 0.007 |
| Median (range) | 48.00 (11.0-68.0) | 49.00 (34.0-66.0) | 0.016 |
| ≤ 20 | 5 (100) | 0 (0) | 0.017 |
| 21-40 | 57 (87.7) | 8 (12.3) | |
| 41-60 | 164 (82.4) | 35 (17.6) | |
| > 60 | 11 (57.9) | 8 (42.1) | |
| Pretreatment conditions/comorbidities | |||
| HCV/HIV coinfection | 4 (100) | 0 (0) | 0.350 |
| Diabetes mellitus | 21 (91.3) | 2 (8.7) | 0.238 |
| Previous alcohol consumption | 45 (81.8) | 10 (18.2) | 0.919 |
| High pretreatment ALT (> 40) | 166 (81.8) | 37 (18.2) | 0.722 |
| High pretreatment Hgb (≥ 12 g/dL) | 182 (81.3) | 42 (18.8) | 0.386 |
| High pretreatment WBC (≥ 4000 mm3) | 225 (82.7) | 47 (17.3) | 0.432 |
| High pretreatment platelet (≥ 150000/mm3) | 189 (84.8) | 34 (15.2) | 0.043 |
| High pretreatment albumin (≥ 3.5 g/dL) | 212 (84.5) | 39 (15.5) | 0.012 |
| High pretreatment HCV RNA (≥ 800000 IU/mL) | 144 (79.1) | 38 (20.9) | 0.065 |
| Liver stiffness | |||
| F ≤ 2 | 133 (92.4) | 11 (7.6) | < 0.001 |
| F3-4 | 104 (72.2) | 40 (27.8) | |
| IL-28B polymorphism | |||
| rs8099917TT | 204 (82.3) | 44 (17.7) | 0.634 |
| rs8099917Non-TT | 18 (78.3) | 5 (21.7) | |
| Unknown | 15 (88.2) | 2 (11.8) | |
| rs12979860CC | 196 (82.4) | 42 (17.6) | 0.618 |
ALT: Alanine aminotransferase; HCV: Hepatitis C virus; Hgb: Hemoglobin; HIV: Human immunodeficiency virus; SVR: Sustained virologic response; WBC: White blood cell.